{
    "clinical_study": {
        "@rank": "15137", 
        "arm_group": {
            "arm_group_label": "All subjects", 
            "arm_group_type": "Experimental", 
            "description": "All subjects will receive a single oral midazolam dose on Day 1 while fasting.  Days 2 to 4 will be Washout days.  On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting."
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the effects of telotristat ethyl on the pharmacokinetics\n      of midazolam in healthy male and female subjects."
        }, 
        "brief_title": "A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects", 
        "condition": "Drug Interactions", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult males and females \u226518 to \u226455 years of age at Screening.\n\n          -  Body mass index \u226518.0 to \u22642.0 kg/m^2\n\n          -  Acceptable vital signs at Screening:  Systolic blood pressure = 90-140 mm Hg,\n             Diastolic blood pressure = 50-90 mm Hg, Heart rate = 40-100 beats per minute\n\n          -  Willingness to adhere to the restrictions outlines in the protocol\n\n          -  Able to comprehend and sign the informed consent form.\n\n        Exclusion Criteria:\n\n          -  Presence of any clinically significant physical, laboratory, or ECG finding that may\n             interfere with the study in the opinion of the Investigator\n\n          -  Use of any medications, herbal tea, energy drink, herbal products, or supplements\n\n          -  Receipt of any investigational agent or study drug within 30 days or 5 half-lives of\n             study start\n\n          -  Receipt of any protein- or antibody-based therapeutic agent within 3 months of study\n             start\n\n          -  Prior exposure to telotristat etiprate\n\n          -  Use of tobacco, smoking cessation products, or nicotine products within 3 months of\n             study start\n\n          -  History of major surgery within 6 months of study start\n\n          -  History of acute narrow angle glaucoma\n\n          -  History of renal disease, or significantly abnormal glomerular filtration rate (<90\n             mL/min as calculated using the Cockcroft-Gault equation) at Screening\n\n          -  History of hepatic disease, or significantly abnormal liver function tests\n\n          -  History of any clinically significant psychiatric, renal, hepatic, pancreatic,\n             cardiovascular, neurological, endocrinologic, hematological, or GI abnormality\n\n          -  History of any active infection within 14 days prior to first dosing\n\n          -  History of alcohol or substance abuse within 2 years prior to Screening\n\n          -  Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus\n             antibody) or positive human immunodeficiency virus antibody screens\n\n          -  Concurrent conditions that could interfere with safety and/or tolerability\n             measurements\n\n          -  Donation or loss of >500 mL of blood or blood product within 3 months\n\n          -  Women who are breastfeeding or are planning to become pregnant during the study\n\n          -  Positive serum pregnancy test (females only)\n\n          -  Positive urine screen for selected drugs of abuse and cotinine\n\n          -  Consumption of alcohol within 48 hours prior to study start\n\n          -  Consumption of caffeine- and/or xanthine-containing products\n\n          -  Consumption of grapefruit, Seville oranges, and grapefruit- or Seville\n             orange-containing products within 72 hours prior to study start\n\n          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason\n\n          -  Use of any drugs or substances that are known to be substrates, inducers, or\n             inhibitors of CYP3A4 within 30 days prior to the first dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147808", 
            "org_study_id": "LX1606.1-108-NRM", 
            "secondary_id": "LX1606.108"
        }, 
        "intervention": [
            {
                "arm_group_label": "All subjects", 
                "description": "All subjects will receive two 250 mg telotristat etiprate tablets three times daily.", 
                "intervention_name": "Telotristat etiprate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "All subjects", 
                "description": "All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Lexicon Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Single-Center, 2-Period, Single-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Multiple-Dose Telotristat Etiprate on the Pharmacokinetics of Single-Dose Midazolam, a Sensitive P450-3A4 Substrate, in Healthy Male and Female Subjects", 
        "overall_contact": {
            "last_name": "Mike Kelly, Project manager", 
            "phone": "281-863-3026"
        }, 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Suman Wason, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Midazolam plasma concentration in combination with steady state telotristat etiprate", 
            "safety_issue": "No", 
            "time_frame": "Day 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147808"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of treatment emergent adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 days"
        }, 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}